| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/20/2023 | 53.77% | Goldman Sachs | $37 → $32 | Maintains | Buy |
| 10/10/2023 | 63.38% | Stephens & Co. | → $34 | Reiterates | Overweight → Overweight |
| 08/09/2023 | 10.52% | Morgan Stanley | $22 → $23 | Maintains | Underweight |
| 08/09/2023 | 68.19% | Needham | $34 → $35 | Maintains | Buy |
| 05/08/2023 | 44.16% | Stephens & Co. | → $30 | Reiterates | → Overweight |
| 02/23/2023 | 63.38% | Needham | $33 → $34 | Maintains | Buy |
| 01/18/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 01/05/2023 | 58.58% | Scotiabank | → $33 | Initiates Coverage On | → Sector Outperform |
| 11/04/2022 | 5.72% | Morgan Stanley | $23 → $22 | Maintains | Underweight |
| 11/04/2022 | 29.75% | Raymond James | $31 → $27 | Maintains | Outperform |
| 11/03/2022 | 58.58% | Needham | $31 → $33 | Maintains | Buy |
| 11/03/2022 | 68.19% | SVB Leerink | $30 → $35 | Maintains | Outperform |
| 08/04/2022 | 48.97% | Raymond James | $30 → $31 | Maintains | Outperform |
| 08/03/2022 | 48.97% | Needham | $26 → $31 | Maintains | Buy |
| 05/05/2022 | 44.16% | Stephens & Co. | $44 → $30 | Maintains | Overweight |
| 05/04/2022 | 10.52% | Morgan Stanley | $25 → $23 | Maintains | Underweight |
| 05/04/2022 | 44.16% | Raymond James | $34 → $30 | Maintains | Outperform |
| 05/04/2022 | 24.94% | Needham | $31 → $26 | Maintains | Buy |
| 03/15/2022 | 48.97% | Needham | $35 → $31 | Maintains | Buy |
| 03/02/2022 | 111.44% | Stephens & Co. | $52 → $44 | Maintains | Overweight |
| 03/01/2022 | 63.38% | Raymond James | $62 → $34 | Maintains | Outperform |
| 03/01/2022 | 92.22% | SVB Leerink | $45 → $40 | Maintains | Outperform |
| 01/07/2022 | 149.88% | Stephens & Co. | → $52 | Initiates Coverage On | → Overweight |
| 11/10/2021 | 197.93% | Raymond James | $50 → $62 | Maintains | Outperform |
| 07/30/2021 | 101.83% | Morgan Stanley | $45 → $42 | Maintains | Underweight |
| 07/30/2021 | 164.3% | Needham | $54 → $55 | Maintains | Buy |
| 07/30/2021 | 188.32% | SVB Leerink | $55 → $60 | Maintains | Outperform |
| 07/14/2021 | 164.3% | SVB Leerink | $65 → $55 | Maintains | Outperform |
| 06/28/2021 | 140.27% | Raymond James | $45 → $50 | Maintains | Outperform |
| 06/15/2021 | 116.24% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
| 05/18/2021 | 164.3% | Truist Securities | $84 → $55 | Maintains | Buy |
| 05/12/2021 | 116.24% | Morgan Stanley | $65 → $45 | Maintains | Underweight |
| 05/11/2021 | 212.35% | SVB Leerink | $75 → $65 | Maintains | Outperform |
| 05/11/2021 | 159.49% | Needham | $88 → $54 | Maintains | Buy |
| 02/22/2021 | 212.35% | Morgan Stanley | $35 → $65 | Maintains | Underweight |
| 02/19/2021 | 212.35% | Morgan Stanley | $35 → $65 | Maintains | Underweight |
| 02/18/2021 | 308.46% | SVB Leerink | $83 → $85 | Maintains | Outperform |
| 02/08/2021 | 298.85% | SVB Leerink | $40 → $83 | Maintains | Outperform |
| 01/28/2021 | 193.13% | Truist Securities | → $61 | Initiates Coverage On | → Buy |
| 11/10/2020 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 11/04/2020 | 101.83% | BTIG | $38 → $42 | Maintains | Buy |
| 11/03/2020 | 92.22% | Needham | $37 → $40 | Maintains | Buy |
| 11/03/2020 | 92.22% | SVB Leerink | $37 → $40 | Maintains | Outperform |
| 09/09/2020 | 68.19% | Morgan Stanley | → $35 | Initiates Coverage On | → Underweight |
| 07/31/2020 | 77.8% | SVB Leerink | $32 → $37 | Maintains | Outperform |
| 07/31/2020 | 77.8% | Needham | $30 → $37 | Maintains | Buy |
| 05/07/2020 | 53.77% | SVB Leerink | $29 → $32 | Maintains | Outperform |
| 02/26/2020 | 44.16% | Needham | $34 → $30 | Maintains | Buy |
| 07/31/2019 | — | Lake Street | Initiates Coverage On | → Buy | |
| 07/02/2019 | 58.58% | Needham | → $33 | Initiates Coverage On | → Buy |
| 11/29/2018 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral |
What is the target price for Veracyte (VCYT)?
The latest price target for Veracyte (NASDAQ: VCYT) was reported by Goldman Sachs on October 20, 2023. The analyst firm set a price target for $32.00 expecting VCYT to rise to within 12 months (a possible 53.77% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Veracyte (VCYT)?
The latest analyst rating for Veracyte (NASDAQ: VCYT) was provided by Goldman Sachs, and Veracyte maintained their buy rating.
When is the next analyst rating going to be posted or updated for Veracyte (VCYT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on October 20, 2023 so you should expect the next rating to be made available sometime around October 20, 2024.
Is the Analyst Rating Veracyte (VCYT) correct?
While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a maintained with a price target of $37.00 to $32.00. The current price Veracyte (VCYT) is trading at is $20.81, which is out of the analyst's predicted range.